Vir Biotechnology (VIR) Liabilities and Shareholders Equity (2018 - 2026)

Vir Biotechnology's Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $1.0 billion for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 21.57% year-over-year to $1.0 billion; the TTM figure through Mar 2026 stood at $4.2 billion (down 27.82% YoY), while the FY2025 annual figure was $1.0 billion, down 28.31% from the prior year.
• Liabilities and Shareholders Equity came in at $1.0 billion for Q1 2026 at Vir Biotechnology, up from $1.0 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.9 billion in Q1 2022 to a low of $1.0 billion in Q4 2025.
• A 5-year average of $1.9 billion and a median of $1.8 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity jumped 154.24% in 2022 and slumped 32.71% in 2024, its largest moves.
• Vir Biotechnology's Liabilities and Shareholders Equity stood at $2.8 billion in 2022, then plunged by 31.51% to $1.9 billion in 2023, then dropped by 27.11% to $1.4 billion in 2024, then declined by 28.31% to $1.0 billion in 2025, then increased by 2.27% to $1.0 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.0 billion, $1.0 billion, and $1.0 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison